HSBC TUR.WAR.OP.END. PFE/ DE000HS3P087 /
2024-08-30 9:35:56 AM | Chg.-0.0200 | Bid11:18:56 AM | Ask11:18:56 AM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
4.2000EUR | -0.47% | 4.2300 Bid Size: 10,000 |
4.3200 Ask Size: 10,000 |
Pfizer Inc | 24.1434 USD | 2078-12-31 | Call |
GlobeNewswire
08-16
Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and C...
GlobeNewswire
07-17
Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion ...
GlobeNewswire
06-27
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the E...
GlobeNewswire
06-05
Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Co...
GlobeNewswire
06-03
Valneva Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infectious Diseases
GlobeNewswire
05-16
Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combinatio...
GlobeNewswire
04-30
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervica...
GlobeNewswire
03-22
Gastroenterologists Slow to Adopt Eli Lilly’s Omvoh, Pfizer’s Velsipity, and Takeda’s subcutaneous ...
GlobeNewswire
03-20
Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook
GlobeNewswire
03-07
BNTX DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel B...
GlobeNewswire
03-07
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioNTe...
GlobeNewswire
03-05
LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd...
GlobeNewswire
02-28
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioNTe...
GlobeNewswire
02-28
BNTX DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel B...
GlobeNewswire
02-27
Arch Biopartners Has Pre-IND Meeting With FDA to Discuss Repurposing Cilastatin as a New Treatment t...
GlobeNewswire
02-20
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioNTe...